NanoString said this week that it closed its previously announced underwritten public offering of 5.2 million shares of its common stock at $23 per share.
Abbott CEO Miles White is bullish on the firm's Alinity systems, while Quest and LabCorp see acquisitions as the likely result of further PAMA-related cuts.
The company will use the proceeds in part to develop its Next Generation Profiling offering to analyze cancer genomes, transcriptomes, and proteomes with clinical outcome data.
Genomic Vision announced this week that it has received a second payment from Quest Diagnostics related to the companies' collaboration for the development of new biomarkers to improve the genetic detection of spinal muscular atrophy. The company declined to disclose the amount of the payment.
The company plans to submit its 650- to 700-gene panel, which will include microsatellite instability testing, to the FDA for approval as a companion diagnostic.
